Going Mobile - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Going Mobile
Seven Reasons Why Pharmaceutical Makers Are Adopting Mobile Technology


Pharmaceutical Technology


When companies end their dependence on paperwork, they typically experience productivity increases of 10–25% (2). They also see an improvement in first-time fix rates because their skill teams have more data at the point of performance. The labor savings and increase in productivity easily offset the initial investment costs.

Deploying multiple mobile products that use a single platform technology decreases application costs and results in exponential increases in data for better management.

Conclusion

In the pharmaceutical industry, the adoption of mobile technology is an ongoing trend. Organizations are adopting mobile technology to remain competitive. The seven reasons why mobile technology is taking off in the pharmaceutical industry are straightforward and time-tested. New uses for the technology continue to emerge as operational and organizational experts are exposed to the software and users see its convenience.

Richard W. Padula is president and chief executive officer of Syclo, 1721 Moon Lake Blvd., Suite 300, Hoffman Estates, IL 60169, tel. 847.230.3800,
http://www.syclo.com/.

References

1. C. Garritty and K. El Emam, "Who's Using PDAs? Estimates of PDA Use by Health Care Providers: A Systematic Review of Surveys," J. Med. Internet Res. 8 (2), e7 (2006).

2. Syclo, "Syclo Mobile Results Customer Survey" (Syclo, Hoffman Estates, IL, 2004).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here